Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Melanoma 4Breast Neoplasms 2Uveal Melanoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Octreotide 5Everolimus 5pasireotide 3lanreotide 2Bevacizumab 2surufatinib 1pembrolizumab 1ganitumab 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1azaspirane 1arginyllysine 1TKM-080301 1Sunitinib 1Rose Bengal 1Random Allocation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1CX 3543 1Biological Therapy 1Biological Factors 12-Methoxyestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoid Tumor × Rose Bengal × Clear all
NCT00986661 2022-11-02

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
78 enrolled
BreastDermatologicEndocrineGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡